Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Transkaryotic's ex-CEO settles SEC fraud suit

This article was originally published in Scrip

Executive Summary

The US Securities and Exchange Commissionhas reached a settlement with the former CEO of Transkaryotic Therapies, Richard Selden, who was accused of misleading investors about the US prospects of the enzyme replacement therapy, Replagal (agalsidase alfa), while selling stock to benefit himself. He will pay a $125,000 civil penalty and about $1 million in "ill-gotten gains" and interest.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts